donafenib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

Zhejiang University (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadhepatocellular carcinoma

I am/have/hadmental illness

I am/have/hadmetastasis

I am/have/hadtumor thrombosis

I am/have/hadantiviral therapy

I am/have/hadpd-l1

I am/have/hadprothrombin

I am/have/hadhepatectomy

I am/have/hadgranulocyte colony stimulating factor

I am/have/hadanticoagulants

I am/have/hadstroke

I am/have/hadcoagulopathy

I am/have/hadplatelet count

I am/have/hadadjuvant therapy

I am/have/hadrecurrent tumor

I am/have/hadhypertension

I am/have/hadhepatitis

I am/have/hadascites

I am/have/hadheart failure

I am/have/hadgastrointestinal hemorrhage

added new label for I am/have/had

more

I am looking for

I am looking fordonafenib

I am looking forantiviral drugs

I am looking forprothrombin

I am looking forimmunomodulator

I am looking forcorticosteroids

I am looking forgranulocyte colony stimulating factor

I am looking foranticoagulants

I am looking forhepatitis b surface antigen

I am looking forsorafenib

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with more than 700,000 new cases in the world every year. China has the highest incidence and death rate of HCC in the world, accounting for 55% of the world's annual incidence and 45% of the world's annual deaths. …

hepatocellular carcinoma

donafenib

tumor thrombosis

metastasis

granulocyte colony stimulating factor

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.